IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 6, Issue 20, April 2026

Impact Factor: 8.2

Advances in Understanding Dry Eye Disease Associated with Silicone Hydrogel Contact Lens Use

Breetha Nagarani.N[1] and Dr. Pankaj M Gajbhiye[2]

[1]Research Scholar, Department of Optometry

[2] Research Guide, Department of Optometry

Sunrise University, Alwar, Raj., India

Abstract: *Dry Eye Disease is one of the most prevalent complications associated with contact lens wear, significantly affecting patient comfort, visual performance, and long-term compliance. Silicone hydrogel contact lenses were introduced to overcome the limitations of conventional hydrogel lenses by providing superior oxygen permeability and reducing corneal hypoxia. Although these lenses have improved ocular physiology and enabled extended wear, dry eye symptoms remain a major challenge among users. Recent research has revealed that DED associated with silicone hydrogel lenses is a multifactorial condition involving tear film instability, meibomian gland dysfunction, inflammatory responses, mechanical friction, and alterations in ocular surface homeostasis.*

Advances in ocular surface imaging, tear film analysis, and biomarker identification have improved understanding of the pathophysiological mechanisms underlying contact lens-related dry eye. Furthermore, novel therapeutic approaches, including drug-eluting silicone hydrogel lenses, hyaluronic acid coatings, osmoprotective agents, and anti-inflammatory treatments, have demonstrated promising results in alleviating symptoms. This review examines recent advances in understanding the relationship between silicone hydrogel contact lens use and dry eye disease, highlighting emerging mechanisms, diagnostic strategies, and future therapeutic directions.

Keywords: Dry Eye Disease, Silicone Hydrogel Contact Lenses, Ocular Surface, Tear Film Instability, Contact Lens Discomfort, Meibomian Gland Dysfunction

I. INTRODUCTION

Dry Eye Disease is a multifactorial disorder of the ocular surface characterized by tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. Contact lens wear is recognized as a major risk factor for the development of dry eye symptoms. Silicone hydrogel contact lenses were introduced in 1999 to enhance oxygen transmission to the cornea and reduce hypoxia-related complications. While these lenses significantly improved corneal health and reduced edema, many wearers continue to report symptoms of dryness, discomfort, and visual fluctuation, particularly during prolonged use. Recent investigations indicate that the etiology of DED in silicone hydrogel lens wearers extends beyond oxygen deprivation and involves complex interactions between the lens material, tear film, eyelids, and ocular surface tissues.

EVOLUTION OF SILICONE HYDROGEL CONTACT LENSES

Silicone hydrogel lenses were developed to address oxygen deficiency associated with traditional hydrogel lenses. Their high oxygen permeability (Dk/t) allows sufficient oxygen supply to the cornea even during extended wear. Studies have demonstrated that silicone hydrogel lenses substantially reduce hypoxic stress, corneal swelling, and limbal hyperemia compared with conventional hydrogel lenses. However, despite these benefits, discomfort and dry eye symptoms remain among the leading causes of contact lens discontinuation.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 20, April 2026
Impact Factor: 8.2

PATHOPHYSIOLOGY OF DRY EYE DISEASE IN SILICONE HYDROGEL LENS WEARERS

1. Tear Film Instability

The tear film plays a crucial role in maintaining ocular surface health. Silicone hydrogel lenses can disrupt tear film dynamics by altering tear distribution and increasing evaporation rates. Reduced tear film stability results in ocular surface desiccation and symptomatic dryness. Recent imaging studies have shown shortened tear breakup time among symptomatic silicone hydrogel lens users.

2. Mechanical Interaction and Friction

Although silicone hydrogel materials provide excellent oxygen transmission, their relatively higher modulus can increase friction between the lens and ocular tissues. Mechanical stress contributes to lid wiper epitheliopathy, superior epithelial arcuate lesions, and conjunctival changes that may exacerbate dry eye symptoms.

3. Inflammatory Responses

Emerging evidence suggests that ocular surface inflammation plays a central role in contact lens-related DED. Chronic lens wear may stimulate inflammatory cytokines, matrix metalloproteinases, and immune mediators, leading to epithelial damage and tear film instability. Inflammation perpetuates a vicious cycle of dryness and ocular discomfort.

4. Meibomian Gland Dysfunction

Meibomian glands secrete lipids essential for preventing tear evaporation. Long-term contact lens wear has been associated with structural changes and dropout of meibomian glands, resulting in evaporative dry eye. Recent studies identify meibomian gland dysfunction (MGD) as a major contributor to contact lens discomfort.

Table 1. Major Mechanisms of Silicone Hydrogel Contact Lens-Related Dry Eye Disease

Mechanism	Pathophysiological Effect	Clinical Consequence
Tear film instability	Increased evaporation and reduced tear breakup time	Ocular dryness
Mechanical friction	Epithelial microtrauma and lid wiper damage	Discomfort and irritation
Inflammation	Cytokine release and ocular surface damage	Chronic dry eye symptoms
Meibomian gland dysfunction	Reduced lipid secretion	Evaporative dry eye
Lens deposits	Altered wettability and tear interaction	Visual fluctuation and discomfort

1. **Recent Advances in Diagnosis**

Several technological advances have improved the diagnosis of contact lens-related DED:

2. Non-invasive Tear Break-Up Time (NIBUT)

Provides objective measurement of tear film stability without fluorescein dye.

3. Meibography

Allows visualization of meibomian gland structure and assessment of gland dropout.

4. Tear Osmolarity Analysis

Measures tear hyperosmolarity, a hallmark of dry eye disease.

5. Inflammatory Biomarkers

Detection of inflammatory mediators such as MMP-9 and cytokines has improved identification of subclinical ocular surface inflammation.

EMERGING THERAPEUTIC APPROACHES

Dry Eye Disease (DED) associated with silicone hydrogel contact lens wear remains a significant clinical challenge despite substantial advancements in contact lens materials and ocular surface management. Traditional treatment strategies such as artificial tears, lubricating eye drops, and modifications in lens wear schedules often provide only temporary relief and may not adequately address the underlying mechanisms responsible for disease progression. Consequently, recent years have witnessed the emergence of innovative therapeutic approaches aimed at targeting the multifactorial pathophysiology of contact lens-related dry eye disease. These approaches focus on improving tear film stability, reducing ocular surface inflammation, enhancing lens biocompatibility, restoring meibomian gland function, and utilizing advanced drug delivery technologies. The integration of biomaterials science, nanotechnology, regenerative medicine, and precision therapeutics has opened new avenues for improving patient outcomes and contact lens tolerance (Jones et al., 2021).

One of the most promising developments in the treatment of contact lens-associated dry eye is the introduction of drug-eluting silicone hydrogel contact lenses. Conventional eye drops often suffer from poor bioavailability because a significant proportion of the administered drug is rapidly eliminated through blinking and tear drainage. Drug-eluting contact lenses are designed to incorporate therapeutic agents directly into the lens matrix, allowing controlled and sustained release of medications onto the ocular surface over extended periods. These lenses can deliver lubricants, anti-inflammatory drugs, osmoprotective compounds, and secretagogues more efficiently than conventional topical therapies. Studies have demonstrated that silicone hydrogel lenses loaded with hyaluronic acid, dexamethasone, cyclosporine A, and diquafosol significantly improve tear film stability and reduce symptoms of dryness and discomfort among lens wearers (Maulvi et al., 2022).

Another emerging therapeutic strategy involves the use of hyaluronic acid-coated silicone hydrogel lenses. Hyaluronic acid is a naturally occurring glycosaminoglycan with exceptional water-retention capacity and biocompatibility. Surface modification of silicone hydrogel lenses with hyaluronic acid enhances lens wettability, decreases friction between the lens and ocular tissues, and improves moisture retention throughout the wearing period. These properties contribute to increased comfort and reduced ocular surface irritation. Clinical investigations have reported that patients wearing hyaluronic acid-coated lenses experience improved tear breakup time, reduced corneal staining, and lower subjective discomfort scores compared with conventional silicone hydrogel lens users (Pult & Nichols, 2020).

Nanotechnology-based ocular drug delivery systems represent another significant advancement in dry eye management. Nanoparticles, nanogels, liposomes, and nano emulsions are increasingly being utilized to improve the delivery of therapeutic agents to the ocular surface. Nanocarriers provide enhanced drug stability, prolonged retention time, and controlled release characteristics. In the context of contact lens-associated dry eye, nanoparticle-loaded lenses have demonstrated the ability to deliver anti-inflammatory and lubricating agents directly to ocular tissues while minimizing systemic exposure. Researchers have developed silicone hydrogel lenses embedded with polymeric nanoparticles containing cyclosporine A, tacrolimus, and corticosteroids, achieving sustained drug release over several days. Such technologies have the potential to revolutionize dry eye treatment by reducing treatment frequency and improving patient adherence (Guo et al., 2022).

Inflammation plays a central role in the pathogenesis of dry eye disease, making anti-inflammatory therapies a critical component of emerging treatment strategies. Contemporary research has focused on identifying specific inflammatory pathways involved in ocular surface damage and developing targeted therapies to interrupt these processes. Topical cyclosporine A has become a widely accepted treatment for moderate-to-severe dry eye by suppressing T-cell activation and reducing inflammatory cytokine production. Similarly, lifitegrast, a lymphocyte function-associated antigen-1 (LFA-1) antagonist, inhibits inflammatory cell recruitment and has demonstrated significant efficacy in reducing dry eye symptoms. Newer biologic agents targeting interleukins, tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinases are currently under investigation and may provide additional therapeutic options for patients with severe inflammatory dry eye associated with contact lens wear (Craig et al., 2017).

Advances in regenerative medicine have also generated considerable interest in the treatment of ocular surface disorders. Autologous serum eye drops, platelet-rich plasma preparations, and growth factor-based therapies are increasingly being used to promote epithelial healing and restore ocular surface integrity. These biological treatments contain essential growth factors, vitamins, and cytokines that support tissue regeneration and reduce inflammation. Clinical studies have demonstrated that autologous serum therapy improves tear film quality, corneal epithelial health, and patient-reported symptoms in individuals with severe dry eye disease. Emerging evidence suggests that regenerative approaches may be particularly beneficial for contact lens wearers experiencing chronic ocular surface damage and persistent discomfort (Pan et al., 2017).

Meibomian gland dysfunction (MGD) is recognized as one of the leading contributors to evaporative dry eye among contact lens users. Recent therapeutic innovations specifically targeting meibomian gland health have shown encouraging results. Thermal pulsation systems utilize controlled heat and pressure to remove gland obstructions and restore lipid secretion. Devices such as LipiFlow and similar technologies have demonstrated significant improvements in meibomian gland function, tear film stability, and symptom relief. Intense Pulsed Light (IPL) therapy has emerged as another effective treatment for MGD by reducing inflammation, improving glandular secretion, and decreasing bacterial colonization along the eyelid margin. Studies indicate that IPL treatment can significantly reduce evaporative tear loss and improve comfort in patients with contact lens-related dry eye symptoms (Arita et al., 2019).

Osmoprotective therapies represent another innovative approach in dry eye management. Tear hyperosmolarity is considered a central pathogenic factor in dry eye disease and contributes to epithelial cell stress and inflammation. Osmoprotective agents such as betaine, erythritol, trehalose, and L-carnitine help protect ocular surface cells against osmotic damage. Recent research has explored the incorporation of osmoprotectants into silicone hydrogel contact lenses, enabling continuous delivery to the ocular surface. Vitamin E-modified lenses have been developed to prolong the release of osmoprotective compounds, resulting in improved tear film stability and sustained symptom relief. These advances provide a novel method for addressing one of the fundamental mechanisms underlying dry eye disease (Peng et al., 2022).

Artificial intelligence (AI) and digital health technologies are increasingly being integrated into dry eye diagnosis and treatment. AI-assisted imaging systems can analyze tear film characteristics, meibomian gland morphology, and ocular surface abnormalities with high accuracy. These technologies facilitate early detection of disease progression and enable personalized treatment planning. Furthermore, smart contact lenses equipped with biosensors are being developed to monitor tear composition, osmolarity, and inflammatory biomarkers in real time. Such innovations may allow clinicians to identify early signs of ocular surface dysfunction and initiate targeted interventions before significant symptoms develop. The convergence of AI, wearable technologies, and ophthalmology is expected to transform the future management of contact lens-associated dry eye disease (Nichols et al., 2021).

Another emerging area involves biomimetic and bioengineered contact lens materials designed to replicate the natural properties of the ocular surface. Advanced surface treatments aim to improve wettability, reduce protein and lipid deposition, and minimize mechanical irritation. Researchers are developing hydrogel materials incorporating mucin-mimetic polymers and phospholipid coatings that more closely resemble the natural tear film environment. These bioinspired designs may significantly enhance comfort and reduce the incidence of contact lens-related dry eye symptoms. Additionally, self-lubricating and responsive materials capable of adjusting their properties according to environmental conditions are being investigated as next-generation contact lens technologies (Subbaraman & Jones, 2020).

Emerging therapeutic approaches for silicone hydrogel contact lens-associated dry eye disease are rapidly transforming the clinical landscape. Innovations such as drug-eluting contact lenses, nanotechnology-based delivery systems, anti-inflammatory biologics, regenerative medicine, meibomian gland therapies, osmoprotective treatments, artificial intelligence-driven diagnostics, and bioengineered lens materials offer promising opportunities for improving patient comfort and ocular health. As research continues to advance, these therapies are expected to provide more personalized, effective, and long-lasting solutions for managing dry eye disease among contact lens wearers, ultimately enhancing quality of life and promoting successful long-term lens use.

1. Drug-Eluting Silicone Hydrogel Lenses

Recent research has focused on incorporating therapeutic agents directly into silicone hydrogel lenses. These lenses can provide sustained release of medications such as hyaluronic acid, diquafosol, betaine, and anti-inflammatory compounds, thereby improving tear stability and reducing symptoms.

2. Hyaluronic Acid Surface Modification

Hyaluronic acid coatings enhance lens wettability, reduce protein deposition, and improve wearer comfort. Modified silicone hydrogel lenses demonstrate prolonged moisture retention and reduced ocular surface friction.

3. Vitamin E Barrier Technology

Vitamin E-loaded silicone hydrogel lenses have been shown to prolong the release of osmoprotective agents such as betaine, significantly reducing tear film evaporation and dry eye symptoms.

4. Advanced Anti-Inflammatory Therapies

Novel anti-inflammatory approaches targeting inflammatory pathways involved in DED are under investigation. These therapies aim to restore ocular surface homeostasis and prevent chronic disease progression.

Table 2. Recent Therapeutic Innovations for Silicone Hydrogel Lens-Associated DED

Innovation	Mechanism	Reported Benefit
Hyaluronic acid-coated lenses	Enhanced wettability	Improved comfort
Drug-eluting lenses	Sustained drug delivery	Reduced inflammation
Vitamin E-loaded lenses	Controlled release of osmoprotectants	Extended symptom relief
Diquafosol-loaded lenses	Increased tear secretion	Improved tear stability
Anti-inflammatory hydrogels	Cytokine suppression	Reduced ocular surface damage

II. CONCLUSION

Silicone hydrogel contact lenses have revolutionized contact lens practice by reducing hypoxia-related complications and improving ocular physiology. Nevertheless, dry eye disease remains a significant concern among lens wearers. Contemporary research indicates that DED associated with silicone hydrogel lenses results from a complex interaction of tear film instability, mechanical stress, inflammation, and meibomian gland dysfunction. Advances in diagnostic technologies and therapeutic innovations, particularly drug-eluting and surface-modified silicone hydrogel lenses, offer promising opportunities for improving patient comfort and ocular health. Continued investigation into the biological mechanisms of contact lens-related dry eye will support the development of safer and more effective lens technologies.

REFERENCES

[1]. Arita, R., Mizoguchi, T., Kawashima, M., (2019). Meibomian gland dysfunction and treatment strategies. *Cornea*, 38(1), 1–8.

[2]. Craig, J. P., Nichols, K. K., Akpek, E. K., (2017). TFOS DEWS II Definition and Classification Report. *The Ocular Surface*, 15(3), 276–283.

[3]. Guo, H., Li, J., Yang, X., (2022). Recent advances in hydrogels for diagnosis and treatment of dry eye disease. *Gels*, 8(12), 816.

[4]. Jones, L., Downie, L. E., Korb, D., (2021). TFOS Lifestyle Report. *The Ocular Surface*, 19, 9–74.

[5]. Lin, M. C., & Yeh, T. N. (2013). Mechanical complications induced by silicone hydrogel contact lenses. *Eye & Contact Lens*, 39(1), 115–124.

[6]. Maulvi, F. A., Soni, T. G., & Shah, D. O. (2022). Drug-eluting contact lenses for ocular therapy. *Journal of Controlled Release*, 349, 1020–1038.

[7]. Nichols, K. K., Foulks, G. N., Bron, A. J., (2021). Emerging technologies in dry eye disease diagnosis. *Progress in Retinal and Eye Research*, 82, 100915.

[8]. Pan, Q., Angelina, A., Marrone, M., (2017). Autologous serum eye drops for dry eye. *Cochrane Database of Systematic Reviews*, 2, CD009327.

[9]. Peng, C. C., Kim, J., Chauhan, A. (2022). Vitamin E-loaded contact lenses for dry eye treatment. *Acta Biomaterialia*, 139, 45–58.

[10]. Pult, H., & Nichols, J. J. (2020). A review of hyaluronic acid applications in contact lens wear. *Contact Lens and Anterior Eye*, 43(4), 315–324.

[11]. Stapleton, F., Stretton, S., Papas, E., Skotnitsky, C., & Sweeney, D. F. (2006). *Silicone hydrogel contact lenses and the ocular surface*. Ocular Surface, 4(1), 24–43.

[12]. Subbaraman, L. N., & Jones, L. (2020). Contact lens materials and ocular surface interactions. *Eye & Contact Lens*, 46(5), 257–264.

ISSN: 2581-9429

Volume 6, Issue 20, April 2026

Impact Factor: 8.2

[13]. Travis, L., (2024). Silicone hydrogel versus hydrogel soft contact lenses for differences in patient-reported eye comfort and safety. *Optometry and Vision Science*, 101(2), 91–99.

[14]. Yang, N., Mu, J., Xu, F., (2026). Advances in dry eye disease: From immunopathological mechanisms to emerging ophthalmic drug delivery systems. *Frontiers in Medicine*, 13, 1780733.

DOI: 10.48175/568